Drug Profile
Dapagliflozin - AstraZeneca
Alternative Names: Andatang; AZ-dapagliflozin; BMS-512148; BMS-dapagliflozin; BMS/AZ-Dapagliflozin; DAPA; Dapagliflozin-AstraZeneca; Dapagliflozin-propanediol; Farxiga; Forxiga; OxraLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer AstraZeneca; AstraZeneca KK; Bayer; Bristol-Myers Squibb; Novo Nordisk Foundation; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
- Class Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Phase III COVID 2019 infections; Heart failure; Myocardial infarction
- Phase II Kidney disorders; Liver cirrhosis; Obesity; Prediabetic state
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure(In the elderly, Prevention) in Australia (PO, Tablet)
- 19 Mar 2024 AstraZeneca plans a phase III trial in Chronic heart failure (Combination therapy) in USA, Argentina, Australia, Austria, Canada, Chile, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Kores, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, Vietnam (NCT06307652)
- 11 Nov 2023 Efficacy data from a phase III trial in Heart failure presented at the the American Heart Association Scientific Sessions 2023 (AHA-2023)